Analyst picks & changes

Protein Design Labs Inc.


Business: Antibodies

Oppenheimer & Co. analyst Matthew Geller said that the failure of the company's Zenapax anti-Tac humanized antibody to prevent graft-versus-host disease wasn't a surprise to many on the

Read the full 350 word article

How to gain access

Continue reading with a
two-week free trial.